156 related articles for article (PubMed ID: 28678537)
1. Pharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas.
Ferrero S; Leone Roberti Maggiore U; Aiello N; Barra F; Ditto A; Bogani G; Raspagliesi F; Lorusso D
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):881-889. PubMed ID: 28678537
[TBL] [Abstract][Full Text] [Related]
2. Current state of the art and emerging pharmacotherapy for uterine leiomyosarcomas.
Tantari M; Barra F; Di Domenico S; Ferraioli D; Vellone VG; De Cian F; Ferrero S
Expert Opin Pharmacother; 2019 Apr; 20(6):713-723. PubMed ID: 30724615
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors.
Goh BC; Reddy NJ; Dandamudi UB; Laubscher KH; Peckham T; Hodge JP; Suttle AB; Arumugham T; Xu Y; Xu CF; Lager J; Dar MM; Lewis LD
Clin Pharmacol Ther; 2010 Nov; 88(5):652-9. PubMed ID: 20881954
[TBL] [Abstract][Full Text] [Related]
4. Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.
Benson C; Ray-Coquard I; Sleijfer S; Litière S; Blay JY; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla S; Gil T; Piperno-Neumann S; Marréaud S; Dewji MR; van der Graaf WTA
Gynecol Oncol; 2016 Jul; 142(1):89-94. PubMed ID: 27012429
[TBL] [Abstract][Full Text] [Related]
5. A Case of Uterine Leiomyosarcoma with Long-Term Disease Control by Pazopanib.
Nagamata S; Ebina Y; Yamano Y; Miyamoto T; Nishijima M; Yamada H
Kobe J Med Sci; 2016 Jul; 62(2):E45-8. PubMed ID: 27578036
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.
Boudou-Rouquette P; Tlemsani C; Blanchet B; Huillard O; Jouinot A; Arrondeau J; Thomas-Schoemann A; Vidal M; Alexandre J; Goldwasser F
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1433-1444. PubMed ID: 27556889
[TBL] [Abstract][Full Text] [Related]
7. Pazopanib for the treatment of renal cancer.
Al-Marrawi MY; Rini B
Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
[TBL] [Abstract][Full Text] [Related]
8. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics.
Yau T; Chen PJ; Chan P; Curtis CM; Murphy PS; Suttle AB; Gauvin J; Hodge JP; Dar MM; Poon RT
Clin Cancer Res; 2011 Nov; 17(21):6914-23. PubMed ID: 21831954
[TBL] [Abstract][Full Text] [Related]
9. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
[TBL] [Abstract][Full Text] [Related]
10. Pazopanib, a new therapy for metastatic soft tissue sarcoma.
Verweij J; Sleijfer S
Expert Opin Pharmacother; 2013 May; 14(7):929-35. PubMed ID: 23488774
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study.
Koca S; Beşiroğlu M; Özçelik M; Karaca M; Bilici M; Hacıoğlu B; Doğu GG; Kaplan NB; Oruç Z; Aydın D; Dane F
J Oncol Pharm Pract; 2021 Apr; 27(3):541-546. PubMed ID: 32419618
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.
Cesne AL; Bauer S; Demetri GD; Han G; Dezzani L; Ahmad Q; Blay JY; Judson I; Schöffski P; Aglietta M; Hohenberger P; Gelderblom H
BMC Cancer; 2019 Aug; 19(1):794. PubMed ID: 31409302
[TBL] [Abstract][Full Text] [Related]
13. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.
Monk BJ; Mas Lopez L; Zarba JJ; Oaknin A; Tarpin C; Termrungruanglert W; Alber JA; Ding J; Stutts MW; Pandite LN
J Clin Oncol; 2010 Aug; 28(22):3562-9. PubMed ID: 20606083
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
Zivi A; Cerbone L; Recine F; Sternberg CN
Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
[TBL] [Abstract][Full Text] [Related]
15. Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing.
Verheijen RB; Beijnen JH; Schellens JHM; Huitema ADR; Steeghs N
Clin Pharmacokinet; 2017 Sep; 56(9):987-997. PubMed ID: 28185218
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of pazopanib in patients with advanced cancer.
Hurwitz HI; Dowlati A; Saini S; Savage S; Suttle AB; Gibson DM; Hodge JP; Merkle EM; Pandite L
Clin Cancer Res; 2009 Jun; 15(12):4220-7. PubMed ID: 19509175
[TBL] [Abstract][Full Text] [Related]
17. Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib.
Tatsumichi T; Tanaka H; Okazaki T; Takahashi K; Suzuki K; Kawakita K; Houchi H; Kuroda Y; Kosaka S
J Clin Pharm Ther; 2021 Feb; 46(1):223-226. PubMed ID: 33044009
[TBL] [Abstract][Full Text] [Related]
18. Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study
Gelderblom H; Judson IR; Benson C; Merimsky O; Grignani G; Katz D; Freivogel KW; Stein D; Jobanputra M; Mungul A; Manson SC; Sanfilippo R
Acta Oncol; 2017 Dec; 56(12):1769-1775. PubMed ID: 28723233
[TBL] [Abstract][Full Text] [Related]
19. A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.
Haas RL; Gelderblom H; Sleijfer S; van Boven HH; Scholten A; Dewit L; Borst G; van der Hage J; Kerst JM; Nout RA; Hartgrink HH; de Pree I; Verhoef C; Steeghs N; van Coevorden F
Acta Oncol; 2015; 54(8):1195-201. PubMed ID: 25920360
[TBL] [Abstract][Full Text] [Related]
20. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
Brotelle T; Bay JO
Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]